Embla Medical hf: Transactions in relation to Share Buyback Program

Embla Medical bought 45,275 shares under its ongoing buyback program during 8–12 December 2025 at an average price of DKK 36.34 for a total of DKK 1,645,400, bringing its holding to 2,658,196 shares (0.62% of share capital). The Program, intended to reduce share capital and adjust the company’s capital structure, may run until 31 December 2025 (or be discontinued earlier), allows purchases of up to 2,000,000 shares (c.0.46% of current capital) and a total consideration cap of USD 10 million, and is being executed in compliance with MAR and applicable delegated regulation. The transactions are a modest, controlled return of capital consistent with Embla’s capital-allocation policy and are unlikely to materially alter share supply given the program’s limited size.

Analysis

Embla Medical acquired 45,275 shares under its announced buyback program between 8 December and 12 December 2025 at an average price of DKK 36.34, paying DKK 1,645,400 for the tranche. After these transactions the company holds 2,658,196 treasury shares, corresponding to 0.62% of its total share capital as reported.

The Program is described as a mechanism to reduce share capital and adjust the capital structure, may run until 31 December 2025 (or be discontinued earlier), and permits purchases of up to 2,000,000 shares (stated as c.0.46% of current share capital) with a total consideration cap of USD 10 million. The recent purchases represent a small fraction of both the share-quantity allowance and the USD 10m cap, so immediate effects on free float, liquidity and EPS are likely modest.

Repurchases are being executed in compliance with MAR and the Commission’s delegated regulation 2016/1052, which limits regulatory execution risk but leaves strategic optionality for management. Investors should track cumulative buybacks against the program cap, the cadence of daily purchases through company disclosures, and any management commentary that would indicate a material shift in capital-allocation strategy.

Key Decisions for Investors

• Maintain current exposure as the disclosed purchases (DKK 1,645,400) are immaterial to free float, but re-evaluate if the company signals acceleration toward the USD 10 million cap
• Monitor cumulative buyback announcements and daily transaction cadence because a sustained ramp-up before 31 December 2025 would be modestly supportive of share price and EPS
• Avoid tactical trading on this single tranche since liquidity and supply effects are minimal given the program's limited size (up to 2,000,000 shares / c.0.46%)
• Watch for any broader capital-allocation changes (larger buybacks, dividends or M&A commentary) in subsequent releases, as those would materially alter the investment thesis